MYONYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
MYOMO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1.25+0.05 (+4.17%)
Close on Oct 19, 2026
- Market cap
- $53.37M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
65.7%−0.0 pts over 5 years
Operating margin
-35.2%+103.3 pts over 5 years
Net margin
-38.1%+114.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +25.7% | +38.1% | +40.1% | – | |
| Gross profit | +16.0% | +37.9% | +40.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 23.0% | -128.6% | -86.2% | |
| Return on assets | – | -108.5% | -38.5% | |
| Current ratio | 0.38 | 5.03 | 3.30 | |
| Interest coverage | – | -48.0× | – | |
| Inventory turnover | – | 4.5× | 4.5× | |
| Capex to revenue | 0.2% | 0.6% | 4.3% | |
| Diluted shares | 0M | 3M | 42M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Myomo generated $43.76M from operations and spent $3.69M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$43.76M
Used
$3.69M
Capital expenditure$3.69M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-38.1%
×Asset turnover1.01×
×Equity multiplier2.24×
=Return on equity, FY2025-86.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -38.1% | 1.01× | 2.24× | -86.2% |
| FY2024 | -19.0% | 1.15× | 1.69× | -36.7% |
| FY2023 | -42.3% | 1.56× | 1.61× | -106.2% |
| FY2022 | -68.9% | 1.03× | 1.39× | -98.5% |
| FY2021 | -74.9% | 0.80× | 1.29× | -76.9% |
| FY2020 | -152.5% | 0.71× | 1.18× | -128.6% |
| FY2019 | -279.1% | 0.52× | 1.16× | -166.7% |
| FY2018 | -422.1% | 0.22× | 1.18× | -109.3% |
| FY2017 | -776.0% | 0.20× | -3.07× | 475.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$15.57M
- Cash generatingOperating cash flow above zero-$14.51M
- Return on assets improvedROA up on the prior year-42.4% → -36.9%
- Earnings backed by cashOperating cash flow above net income-$14.51M vs -$15.57M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.22 → 3.30
- No dilutionShare count did not rise38M → 42M
- Gross margin improvedGross margin up on the prior year71.23% → 65.70%
- More efficientAsset turnover rose2.23 → 0.97